MM012

MM012 is an investigational mucosal antibody currently in the discovery phase of development by Mucommune. The drug is being developed using Mucommune's proprietary MucoTrapping technology, which involves engineering antibodies to bind to mucins within the mucus layer. This mechanism is designed to trap pathogens or other biological targets in mucus, preventing them from crossing the mucosal barrier and facilitating their natural clearance from the body. While the specific therapeutic target and primary indication for MM012 remain undisclosed, the platform is generally applicable to infectious diseases and inflammatory conditions affecting mucosal surfaces such as the respiratory, gastrointestinal, and reproductive tracts.